Intuitive Surgical, Inc. reported second-quarter 2026 results on July 16, posting $2.89 billion in revenue, up 19% from a year earlier, as worldwide procedures for its da Vinci and Ion systems rose about 16%. The numbers give ISRG stock a fresh catalyst, with the company also saying it placed 468 da Vinci surgical systems, 246 da Vinci 5 systems and 55 Ion systems in the period.
The revenue gain was led by procedure volume, higher da Vinci system leasing revenue and a larger installed base of da Vinci and Ion systems. That installed base reached 11,710 da Vinci systems and 1,096 Ion systems by June 30, while instruments and accessories revenue climbed 18% to $1.73 billion and systems revenue was $685 million.
For investors, the headline growth looks strong, but the quarter was not a clean comparison. Net income included a $28 million benefit after tax from refunds for tariffs paid in prior periods under the International Emergency Economic Powers Act, which lifted both GAAP and non-GAAP results. GAAP net income attributable to Intuitive Surgical was $818 million, or $2.29 per diluted share, while non-GAAP net income was $1.00 billion, or $2.80 per diluted share.
The tariff refund appears to be a one-time item tied to prior payments rather than a recurring source of earnings, so the better read on the quarter is the underlying operating performance beneath it. Even with that adjustment, the report shows a business still growing through procedure demand and a deeper installed base, the two measures investors watch most closely when they value a robotics company.
What happens next is the part the market will keep testing: whether Intuitive can keep procedure growth and system placements moving at this pace without help from one-off benefits. Until the company gives its next update, this quarter leaves ISRG stock tied to a simple question of execution — whether the growth is broad enough to hold when the accounting boost fades.
